1.Screening the High Risk Patient for Gynaecological Cancer.
Yonsei Medical Journal 2002;43(6):717-721
It is often difficult to conclude that improvements in survival with time are due to a screening programme alone. Although a reduction in the death rate from a given cancer may reflect the benefits of early detection or improved treatment, the benefits may also result from lead time bias and over-diagnosis, the former resulting in longer survival of screen-identified cancers because the time before the cancer would have been clinically diagnosed is included in calculations. Furthermore, recent reviews on randomised clinical trials of cancer screening have provided strong evidence that misclassifications in causes of death have been a major problem, leading to an over-estimation of the effectiveness (or alternatively an under-estimation of potential harm) of screening.
Cervix Neoplasms/*diagnosis
;
Endometrial Neoplasms/diagnosis
;
Female
;
Genital Neoplasms, Female/*diagnosis/epidemiology/mortality
;
Human
;
Incidence
;
Ovarian Neoplasms/diagnosis
;
Risk
2.Endometrial cancer risk and survival by tumor MMR status.
Christina M NAGLE ; Tracy A O'MARA ; Yen TAN ; Daniel D BUCHANAN ; Andreas OBERMAIR ; Penny BLOMFIELD ; Michael A QUINN ; Penelope M WEBB ; Amanda B SPURDLE
Journal of Gynecologic Oncology 2018;29(3):e39-
OBJECTIVE: The risk of developing endometrial cancer (EC) and/or survival following a diagnosis of EC might differ by tumor DNA mismatch repair (MMR) status. We assessed the association between tumor MMR status (classified as MMR-proficient, somatic MMR-deficient, germline MMR-deficient) and the risk of developing EC and survival following a diagnosis of EC. METHODS: We analyzed data from women who participated in the Australian National Endometrial Cancer Study (ANECS) conducted between 2005 and 2007. Risk analyses (698 cases/691 population controls) utilized sociodemographic and lifestyle information obtained from telephone interviews at recruitment. For survival analyses (728 cases), patients' clinical data was abstracted from medical records, and survival data were obtained via linkage with the Australian National Death Index. We used logistic regression analysis to evaluate the associations between tumor MMR status and EC risk, and proportional hazards models to perform survival analyses with adjustment of known prognostic factors. RESULTS: Established risk factors for EC did not differ significantly by tumor MMR status. In analyses including all EC subtypes, overall and EC-specific survival did not differ by tumor MMR status. Among women with the most common endometrioid subtype, EC-specific survival was worse for women with somatic MMR-deficient EC compared to women with MMR-proficient EC (hazard ratio [HR]=2.18; 95% confidence interval [CI]=1.19–4.01). CONCLUSION: The risk of EC is not associated with MMR status. Accurate separation of germline from somatic causes of MMR deficiency suggests that patients with endometrioid subtype somatic MMR-deficient tumors have poorer EC-specific survival than those with MMR-proficient tumors, after accounting for other prognostic factors.
Diagnosis
;
DNA Mismatch Repair
;
Endometrial Neoplasms*
;
Female
;
Humans
;
Interviews as Topic
;
Life Style
;
Logistic Models
;
Medical Records
;
Proportional Hazards Models
;
Risk Factors
3.Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference.
Ji Yon Agnes JANG ; Nozomu YANAIHARA ; Eric PUJADE-LAURAINE ; Yoshiki MIKAMI ; Katsutoshi ODA ; Michael BOOKMAN ; Jonathan LEDERMANN ; Muneaki SHIMADA ; Takako KIYOKAWA ; Byoung Gie KIM ; Noriomi MATSUMURA ; Tsunehisa KAKU ; Takafumi KURODA ; Yoko NAGAYOSHI ; Ayako KAWABATA ; Yasushi IIDA ; Jae Weon KIM ; Michael QUINN ; Aikou OKAMOTO
Journal of Gynecologic Oncology 2017;28(4):e54-
There has been significant progress in the understanding of the pathology and molecular biology of rare ovarian cancers, which has helped both diagnosis and treatment. This paper provides an update on recent advances in the knowledge and treatment of rare ovarian cancers and identifies gaps that need to be addressed by further clinical research. The topics covered include: low-grade serous, mucinous, and clear cell carcinomas of the ovary. Given the molecular heterogeneity and the histopathological rarity of these ovarian cancers, the importance of designing adequately powered trials or finding statistically innovative ways to approach the treatment of these rare tumors has been emphasized. This paper is based on the Rare Ovarian Tumors Conference for Young Investigators which was presented in Tokyo 2015 prior to the 5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG).
Consensus
;
Diagnosis
;
Female
;
Humans
;
Molecular Biology
;
Mucins
;
Ovarian Neoplasms*
;
Ovary
;
Pathology
;
Population Characteristics
;
Rare Diseases
;
Research Personnel*